Drug Type Small molecule drug |
Synonyms Ravoxertinib (USAN/INN), GD0 994, GDC-0994 + [1] |
Target |
Action inhibitors |
Mechanism ERK inhibitors(ERK subfamily inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H18ClFN6O2 |
InChIKeyRZUOCXOYPYGSKL-GOSISDBHSA-N |
CAS Registry1453848-26-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 1 | United States | 16 Jun 2015 | |
Metastatic Colorectal Carcinoma | Phase 1 | United States | 16 Jun 2015 | |
metastatic non-small cell lung cancer | Phase 1 | United States | 16 Jun 2015 | |
Neoplasm Metastasis | Phase 1 | United States | 16 Jun 2015 | |
Solid tumor | Phase 1 | United States | 06 Apr 2014 | |
Locally Advanced Malignant Solid Neoplasm | Phase 1 | United States | 21 Jun 2013 | |
Locally Advanced Malignant Solid Neoplasm | Phase 1 | France | 21 Jun 2013 | |
Focal Cortical Dysplasia of Taylor | Preclinical | China | 04 Jun 2024 |
Phase 1 | HR-positive/HER2-low Solid Tumors BRAF Mutation | 47 | qimtfrwxoh(zqaijwpfya) = A single DLT of grade 3 rash occurred at 600 mg pqdsrruxny (sgfebufpsy ) View more | Positive | 15 Mar 2020 | ||
Phase 1 | 24 | (Not Assigned) | jusgpkfvod = hcczgtrntf gvfxbyenil (euwxgzdtli, pazsomenbw - ofszbtffdf) View more | - | 24 Aug 2018 | ||
(COB 20 mg + GDC 200 mg) | jusgpkfvod = knhtqsnrdx gvfxbyenil (euwxgzdtli, tmkiofzenw - uqfnvwwlap) View more |